“…However, the biological revolution led to a fundamental technological discontinuity (Sabatier et al, 2012;De Alcantara and Martens, 2019), in that the discovery and the development of new biochemical drugs require a completely different set of bioscientific technology competences (Bonaccorsi and Vargas, 2010;Sabatier et al, 2012). Therefore, the existing dominant R&D logic of pharmaceutical firms following a single technology development pathway becomes insufficient (Sabatier et al, 2012;Tierney et al, 2013), because the latest advancement of biopharma innovations is often generated at the interface between multiple root biopharma research areas (Allhoff, 2009;Styhre, 2011). In this sense, innovations led by practitioners in DIY laboratories may push forward the frontier of biopharma research from a new angle (Fox, 2014, Seyfried et al, 2014Hecker et al, 2018).…”